Literature DB >> 15195324

Sample sizes for clinical trials with normal data.

Steven A Julious1.   

Abstract

This article gives an overview of sample size calculations for parallel group and cross-over studies with Normal data. Sample size derivation is given for trials where the objective is to demonstrate: superiority, equivalence, non-inferiority, bioequivalence and estimation to a given precision, for different types I and II errors. It is demonstrated how the different trial objectives influence the null and alternative hypotheses of the trials and how these hypotheses influence the calculations. Sample size tables for the different types of trials and worked examples are given. Copyright 2004 John Wiley & Sons, Ltd.

Mesh:

Year:  2004        PMID: 15195324     DOI: 10.1002/sim.1783

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  134 in total

1.  Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System.

Authors:  Elena Ramirez; Olga Laosa; Pedro Guerra; Blanca Duque; Beatriz Mosquera; Alberto M Borobia; Suhua H Lei; Antonio J Carcas; Jesus Frias
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

2.  Progressive retinal structure abnormalities in multiple system atrophy.

Authors:  Carlos E Mendoza-Santiesteban; Jose-Alberto Palma; Jose Martinez; Lucy Norcliffe-Kaufmann; Thomas R Hedges; Horacio Kaufmann
Journal:  Mov Disord       Date:  2015-09-11       Impact factor: 10.338

3.  Binary outcomes are not better than continuous variables in randomized controlled trials.

Authors:  Jan Kottner; David L Streiner
Journal:  J Invest Dermatol       Date:  2013-06-11       Impact factor: 8.551

4.  Myofascial Pain Syndrome in the Elderly and Self-Exercise: A Single-Blind, Randomized, Controlled Trial.

Authors:  Minhee Kim; Minyoung Lee; Yushin Kim; Sejun Oh; Dongshin Lee; BumChul Yoon
Journal:  J Altern Complement Med       Date:  2016-02-24       Impact factor: 2.579

5.  The importance of sample size, log-mean ratios, and intrasubject variability in the acceptance criteria of 108 bioequivalence studies.

Authors:  E Ramirez; P Guerra; O Laosa; B Duque; B Tabares; S H Lei; A J Carcas; J Frias
Journal:  Eur J Clin Pharmacol       Date:  2008-05-21       Impact factor: 2.953

Review 6.  Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Authors:  Vaibhav Salvi; Dilip R Karnad; Gopi Krishna Panicker; Snehal Kothari
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

7.  Comment by J. Schäfer, G. Welzel, F. Wenz on D. Norkus et al. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma. a report on acute toxicity : in: Strahlenther Onkol 2009;185: 715-21 (No. 11) (DOI 10.1007/s00066-009-1982-z).

Authors:  Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2009-11       Impact factor: 3.621

8.  [Compression devices for decongestion therapy : A cross-sectional observational survey of handling, pressure, and comfort].

Authors:  K Protz; S Reich-Schupke; K Klose; M Augustin; K Heyer
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

9.  Noninferiority and equivalence designs: issues and implications for mental health research.

Authors:  Carolyn J Greene; Leslie A Morland; Valerie L Durkalski; B Christopher Frueh
Journal:  J Trauma Stress       Date:  2008-10

10.  Comparing administration of questionnaires via the internet to pen-and-paper in patients with heart failure: randomized controlled trial.

Authors:  Robert C Wu; Kevin Thorpe; Heather Ross; Vaska Micevski; Christine Marquez; Sharon E Straus
Journal:  J Med Internet Res       Date:  2009-02-06       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.